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ABSTRACT: Background: The past decade has
witnessed a highly dynamic and growing expansion of
novel methods aimed at improving the assessment of
Parkinson’s disease with technology (NAM-PD) in labo-
ratory, clinical, and home environments. However, the
current state of NAM-PD regarding their maturity, feasi-
bility, and usefulness in assessing the main PD features
has not been systematically evaluated.
Methods: A systematic review of articles published in
the field from 2005 to 2015 was performed. Of 9,503
publications identified in PubMed and the Web of Sci-
ence, 848 full papers were evaluated, and 588 original
articles were assessed to evaluate the technological,
demographic, clinimetric, and technology transfer readi-
ness parameters of NAM-PD.
Results : Of the studies, 65% included fewer than 30
patients,<50% employed a standard methodology to
validate diagnostic tests, 8% confirmed their results in
a different dataset, and 87% occurred in a clinic or lab.
The axial features domain was the most frequently
studied, followed by bradykinesia. Rigidity and nonmo-
tor domains were rarely investigated. Only 6% of the
systems reached a technology level that justified the
hope of being included in clinical assessments in a use-
ful time period.
Conclusions: This systematic evaluation provides an
overview of the current options for quantitative assess-
ment of PD and what can be expected in the near future.
There is a particular need for standardized and collabora-
tive studies to confirm the results of preliminary initiatives,
assess domains that are currently underinvestigated, and
better validate the existing and upcoming NAM-PD.
VC 2016 International Parkinson and Movement Disorder
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Recently there has been an exponential development
of novel methods to improve the assessment of Parkin-
son’s disease (PD) by using different technologies
(NAM-PD; Supplementary Figure). Wearable sensors,
accelerometers, gyroscopes, magnetometers, smart-
phones, and a plethora of other electronic systems
have been employed to obtain physiological signals
related to motor and nonmotor aspects of the dis-
ease.1-3 Although some of the used technologies are
not new (the first accelerometer was invented by
George Atwood in 1783), they all represent methods
that have recently been investigated and used for the
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assessment of PD. The reasons for this increased adop-
tion are beyond the scope of this review, but all of
these techniques attempt to provide an objective
means to measure aspects of the disease.4,5 Their
intended applications range from the improvement
and prediction of diagnosis to the assessment of dis-
ease progression and the evaluation of care and thera-
py efficacy.6
This systematic review presents a comprehensive
evaluation of the NAM-PD investigated in the past 10
years. Our efforts should be considered in light of oth-
er recent initiatives.2,4,7-9 In addition to a narrative2
and a systematic review9 by some of the authors listed
here, a systematic review on wearable technology for
the assessment of gait and balance has recently been
published.7 None of these reviews provide an exhaus-
tive and comprehensive overview of the current state
of the NAM-PD field and how far (potentially clinical-
ly relevant) quantitative assessment strategies have
been developed. This review combines the strengths of
all of these previous initiatives. It includes information
about both wearable and nonwearable technologies;
covers the assessment approaches of the most relevant
disease domains and complications; follows a strict,
transparent, and exhaustive systematic approach by,
for example, including MeSH and non-MeSH terms;
presents clinimetric information and—for the first
time, to our knowledge—the technology readiness lev-
el (TRL10 of every system reported in the studies eval-
uated; and provides a spreadsheet of these data
extracted from the papers.
After reading this article, clinicians, people with Par-
kinson’s disease (PwP), and other stakeholders will have
an overview of how quantitative assessments of PD have
developed during the course of the recent decade of
innovation, what the options are to date, and what we
can expect in the near future from these technologies.
To fulfill this latter purpose in particular, a list of sys-
tems that are close to being translated into practical use
is provided. In addition, the above-mentioned systematic
spreadsheet containing the extracted information on the
evaluated systems can serve as a living document that
will be regularly updated by the authors. Interested read-
ers are encouraged to use this resource to complement
the manuscript, which in fact can only provide some ini-
tial steps of analysis.
Methods
A systematic search for articles published between Jan-
uary 1, 2005, and January 4, 2016, was conducted in 2
electronic databases (PubMed/Medline and Web of Sci-
ence). Using a Boolean search structure, 3 blocks of key-
words were introduced and connected. The first block
was related to the disease (“Parkinsonian Disorders,”
“Parkinson(s) disease,” “Parkinson Disease, Secondary,”
“Basal Ganglia Diseases,” “Parkinsonism”). The second
block included 45 technology terms related to PD assess-
ment (eg, “Technology /-ies,” “Diagnostic Techniques,
Neurological,” “Assessment,” “Patient Outcome Asses-
sment,” “Accelerometer,” “Smartphone”). The third
block was composed of different keywords describing
12 disease domains. These 12 domains were based on
clinical (eg, cardinal PD features) and technical reason-
ing and on previous reviews.2,9,11,12 Six domains referred
to motor aspects (and are discussed separately in the
Results section), 5 to nonmotor aspects, and 1 to
treatment-related complications (eg, wearing-off and
dyskinesias). Table 1 provides an overview of the num-
ber of studies investigating these domains. The vast
majority of the identified and evaluated references
referred to motor aspects; therefore, the focus of the ini-
tial analyses in this manuscript is on these domains.
Nonmotor features and treatment-related complications
were relatively underrepresented and are therefore not
discussed in detail. Papers that were not covered by
these 12 domains were collected in a miscellaneous cate-
gory. This category includes platforms (eg, telemonitor-
ing and telemedicine systems), studies evaluating driving
skills, and a breath test to distinguish PwP from con-
trols. No detailed results are reported for this category
because of its heterogeneity. A complete description of
the search structure and keywords used is provided in
the supplementary material section.
TABLE 1. New technologies for the assessment of
Parkinsons disease (NAM-PD) published during the past
decade (2005-2015) by disease domain
Domain
Number of references
describing the NAM-PD
(% of all included)
Motor 504 (85.7)
Axial features 212 (36.1)
Bradykinesia 126 (21.4)
Tremor 81 (13.8)
Speech 42 (7.1)
Activity 32 (5.4)
Rigidity 11 (1.9)
Nonmotora 24 (4.1)
Cognition 12 (2.0)
Sleep 9 (1.5)
ANS 2 (0.3)
Neuropsychiatric features 1 (0.2)
Smell 0 (0.0)
Treatment complications 20 (3.4)
Miscellaneous 40 (6.8)
Total, included in the results 588
Not included in the full evaluation processb 260
Total number of references evaluated 848
ANS, autonomous nervous system.
aDetailed information about studies in different domains is available at
http://bit.ly/pd-technologies-database and is presented in a common non-
motor domain in the Results section.
bThese are review papers, technologies used for other applications (eg,
schizophrenia and essential tremors), or references in which a technology
used was discarded after the evaluation.
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The following 3 steps were then performed (Figure 1):
 Identification step: A total of 6,874 papers in the
Web of Science and 6,804 in PubMed/Medline
were identified. After eliminating duplicates,
9,503 papers entered the next step.
 Screening step: One author (A.S.F.) screened the
titles and abstracts. The criteria for the articles
included in the next step were (i) use of an NAM-
PD, (ii) published in English, and (iii) used in
humans.
The exclusion criteria were the following: (i) the use
of only questionnaires/scales, (ii) electromyography,
(iii) electroencephalography, (iv) imaging techniques,
(v) molecular diagnostic/therapeutic methods, (vi)
genetic tests, (vii) established speech recognition sys-
tems (ie, computerized speech lab), (viii) new develop-
ments in deep brain stimulation (DBS), and (ix)
magnetic transcranial stimulation. A total of 848
articles entered the next step.
 Evaluation step: This step was performed by 7
authors (A.S.F., M.E., C.G., D.S., M.A.H.,
J.M.T.v.U., and J.D.) using a standardized web-
based form designed by A.S.F. (http://bit.ly/pd-
technologies). The full text of the 848 articles
were evaluated. Articles underwent a basic evalu-
ation (author, journal, volume, pages, year, and
type of article) and were not evaluated more
extensively (and were not included in the analysis
of this review) if they (i) were reviews (n539),
(ii) reported a therapeutic application of NAM-
PD (n5 65), (iii) did not include NAM-PD
(n5 129), and (iv) were not used to assess PD
(n5 27).
From the remaining 588 original articles, the type of
NAM-PD used and the type of researcher using the
NAM-PD (developers vs nondevelopers) were defined.
The use of an NAM-PD by a nondeveloper reinforced
its validation because it confirmed that the NAM-PD
can be applied in different settings. In addition, its use
by a nondeveloper usually indicates that a system is
more ready to be used. Moreover, demographic char-
acteristics (eg, sample size, stage of the disease, inclu-
sion of a control group, and patients with other
FIG. 1. Flowchart of the systematic search and review process of novel technologies to improve the assessment of Parkinson’s disease (NAM-PD)
in the past decade (2005-2015).
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diseases) were extracted. Then, the clinimetric charac-
teristics were evaluated. The selection of clinimetric
characteristics was based on the literature13-16 and
included accuracy (ie, the degree to which a measure-
ment represents the true value of the attribute being
measured, eg, by providing sensitivity and specificity
measures17, agreement (ie, how well a test measures
the event of interest when compared with a standard,
eg, by using Bland-Altman analyses,18 intraclass corre-
lation coefficients,17 and Kappa values17, responsive-
ness (sensitivity to change), and repeatability (the
stability of the metric over time in a population with-
out an expected change). Despite being used in many
studies, pure statistical correlations (ie, Spearman’s
Rho, Pearson’s R, or r2 from regression models) were
not considered adequate to test the clinimetric proper-
ties of an NAM-PD and hence are not reported in the
results.17,19
Moreover, as mentioned previously, we extracted
information about the TRL of each original article
included in the full evaluation. The TRL scale was
developed by the National Aeronautics and Space
Administration and has recently been adapted by the
European Commission for the Horizon 2020 initia-
tive10 (Supplementary Table). This scale can be
applied by different stakeholders (eg, researchers, clini-
cians, patients, regulatory and funding agencies, and
industrial partners) as a tool to determine how close a
technology is to being translated and for what use. Its
use in biomedical applications has recently begun.
Development of the Systematic
Spreadsheet and Its Proposed Use
Detailed information about all 848 evaluated
articles is available at http://bit.ly/pd-technologies-
database. The systematic table derived from our evalu-
ation is shared publicly for several purposes. First,
interested readers are offered the opportunity to inves-
tigate any facet of the current state of NAM-PD
because the analyses presented in this manuscript are
necessarily limited to certain meta aspects and cannot
provide detailed answers on all aspects. Second, the
authors of the evaluated technologies can peer review
the information systematized by our group. In case of
any inconsistency, we are prepared to adapt the
spreadsheet accordingly. Third, it can serve as a living
document: Because the form used is also shared at
http://bit.ly/pd-technologies, any upcoming studies are
offered the opportunity to be included in this spread-
sheet. To provide an example of the opportunities the
spreadsheet provides, we focus in the Results section
on the presentation of frequency, type of technology
used, demographic aspects, clinimetric properties, and
TRL aspects of studies sorted by different motor fea-
tures. In addition, we include a paragraph each on
nonmotor aspects and treatment complications. The
data are presented as absolute numbers and, in paren-
theses, the percentages of the total of all studies that
provided the information of interest.
Results
Of the 588 fully evaluated articles, 208 (35%)
reported on the validation of NAM-PD by developers,
183 (31%) on NAM-PD performance evaluated by
nondevelopers, 157 (27%) on mathematical algorithms,
and 40 (7%) on future NAM-PD platforms/ideas.
Studies using wearable NAM-PD covered a relevant
proportion of the research performed in this field (211
[37%] included this type of technology), and the num-
ber of published studies showed a substantial relative
increase during the period evaluated. For example,
wearable NAM-PD were used in 3 (18%) of the stud-
ies published in 2005 and in 38 (44%) of the studies
published in 2015. Of the studies, 45 (8%) confirmed
their results in a different dataset.
Basic disease severity information using Hoehn and
Yahr stages was reported in 247 (42%) of the studies.
PwP in stage 2 were most often included (in 216 of
those studies), followed by those in stage 3 (193), 2.5
(154), 1 (120), 4 (77), and 5 (11).
The ages of the participants were included in 394
(76%) of the studies that tested individuals, and 110
studies (20%) included information on the statistical
assumptions (eg, whether the data followed a Gauss-
ian distribution).
The technologies used were accelerometers and
gyroscopes alone or combined, which we categorized
as inertial measurement units (IMUs), digitizing tab-
lets, optoelectronic systems, electromagnetic trackers,
force plates, virtual reality systems, software-based
technologies, smartphones, audio recorders, insoles,
computer vision systems, smart gloves, videogame
consoles and ad hoc solutions.
NAM-PD for the Assessment
of Motor Aspects
Axial Features
Number of Studies. A total of 70 articles (33%)
reported on NAM-PD used by nondevelopers, 68
(32%) on validation aspects, 65 (31%) on a mathemat-
ical algorithm, and 9 (4%) on future NAM-PD plat-
forms/ideas.
Type of Technologies. The most frequently used sys-
tems (106 articles, 50%) were IMUs, followed by
optoelectronic systems (20 articles, 9%).
Demographic Aspects. Of the evaluated studies, 147
(71%) included 30 or fewer PwP. The most frequently
included mean/median age group ranged from 61 to
70 years (101 studies, 69%), followed by 71 to 80
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years in 26 (18%) of the studies, and 51 to 60 years
in 20 (14%) of the studies.
Clinimetric Properties. A total of 49 studies (23%)
performed data diagnostics (eg, normality assumption
tests) prior to conducting statistical analyses. The
most frequently reported reference standard was the
motor section of the Unified Parkinson’s Disease Rat-
ing Scale (UPDRS-III), which was employed in 33
(16%) of the studies. Accuracy was reported in 98
studies (48%). The sensitivity and specificity of the
NAM-PD were higher than 80% in 27 (28%) and 35
(36%) of them, respectively. The areas under the
receiver operating characteristics curve (AUCs) and
the predictive values/likelihood ratios were provided
in 8 (4%) and 5 (2%) of the studies, respectively.
Agreement with a reference standard was described in
26 (13%) of the articles. Of these articles, 19 (73%)
provided evidence of adequate agreement. Responsive-
ness was investigated in 31 (15%) of the articles. The
most frequent method used to induce a change was
pharmacological intervention, which was present in 13
(42%) of these studies. Repeatability was assessed in 6
articles (3%).
Technology Readiness. Of the studies, 85 (45%)
included NAM-PD with a TRL 3, and NAM-PD
with TRL9 were used in 18 (8%) of the studies.
Bradykinesia
Number of Studies. Of the studies, 72 (57%)
reported on the validation of NAM-PD in characteriz-
ing bradykinesia. Thirty-two (25%) involved NAM-PD
used by nondevelopers, 17 (13%) tested a mathemati-
cal algorithm for NAM-PD, and 5 (4%) described an
NAM-PD or idea.
Type of Technologies. The most frequently used sys-
tems were IMUs (39 studies, 31%), followed by a com-
bination of various methods (14 studies, 11%).
Demographic Aspects. Of the studies, 89 (71%) includ-
ed 30 or fewer PwP. The most frequently included mean/
median age group range was 61 to 70 years (73 studies,
85%). With one exception, the mean/median age of the
groups was between 50 and 80 years in all studies.
Clinimetric Properties. Of the studies, 18 (15%) per-
formed data diagnostics prior to conducting any statis-
tical analyses. The most frequently reported reference
standard was the UPDRS-III, which was employed in
41 (34%) of the studies, followed by expert diagnosis
(eg, classification of PD according to established crite-
ria) in 36 (30%) studies.
The accuracy of the NAM-PD was reported in 45
(37%) of the studies. The sensitivity and specificity of
the results generated by NAM-PD were higher than
80% in 10 (22%) and 7 (15%) of the studies, respec-
tively. Of the studies, 11 (9%) and 5 (4%) provided
AUCs and predictive values/likelihood ratios, respec-
tively. Agreement with a reference standard was
described in 10 (8%) of the studies. A total of
8 (60%) of them provided evidence of an adequate
agreement. Responsiveness and repeatability were
investigated in 32 (26%) and 6 (5%) studies, respec-
tively. For the former, the most frequent method
applied to induce a change was a pharmacological
intervention (21 studies, 66%).
Technology Readiness. A total of 94 studies (74%)
included NAM-PD with a TRL 3, and 9 (7%) of the
studies used NAM-PD that reached TRL9.
Tremors
Number of Studies. A total of 33 studies (41%)
reported the validation of NAM-PD in characterizing
tremors, 23 (28%) tested a mathematical algorithm for
NAM-PD, 20 (25%) involved NAM-PD used by nonde-
velopers, and 5 (6%) described an NAM-PD or an idea.
Type of Technologies. The most frequently used sys-
tems were IMUs (38 studies, 47%), followed by smart-
phones, which were used in 11 (14%) of the studies.
Demographic Aspects. A total of 52 (67%) studies
included 30 or fewer PwP. The most frequent mean/
median age group in the studies ranged from 61 to 70
years (29 studies, 10%), and in all studies, the mean/
median age of the participants was between 50 and
80 years.
Clinimetric Properties. A total of 15 studies (20%)
performed data diagnostics prior to conducting statis-
tical analyses. The most frequently reported reference
standard was PD classification according to estab-
lished criteria (14 studies, 18%), followed by the
UPDRS-III (12 studies, 16%).
Accuracy was reported in 35 studies (46%). The
sensitivity and specificity were higher than 80% in 17
(49%) and 14 (40%) studies, respectively. AUCs and
predictive values/likelihood ratios were provided in
8 (10%) and 2 (2%) of the studies, respectively.
Agreement with a reference standard was described in
5 studies (7%), with all of them providing evidence of
an adequate agreement. Of the studies, 6 (8%) investi-
gated responsiveness (3 by pharmacological interven-
tion), and 1 (1%) assessed repeatability.
Technology Readiness. Of the studies, 50 (68%)
included NAM-PD considered to represent TRL1 to
TRL3. Two studies (2%) included NAM-PD of TRL9.
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Speech
Number of Studies. A total of 30 studies (71%) tested
a mathematical algorithm for NAM-PD to characterize
speech, 9 (21%) reported NAM-PD used by nondevel-
opers, and 3 (7%) studies validated an NAM-PD.
Type of Technologies. The most frequently used sys-
tems were audio recorders (8 studies, 19%), followed
by software-based solutions (6 studies, 14%). A total
of 24 studies (57%) investigated mathematical algo-
rithms without an additional hardware or software
component.
Demographic Aspects. Of the studies, 24 (62%) that
provided information on cohort size included 30 or
fewer PwP. The most frequent mean/median age group
ranged from 61 to 70 years (24 studies, 92%), and the
mean/median age of the participants in all studies was
between 50 and 80 years.
Clinimetric Properties. A total of 8 studies (19%)
performed data diagnostics. The most frequently
reported reference standard was PD classification
according to established criteria (16 studies, 38%),
followed by UPDRS-III (7 studies, 17%). Accuracy
was reported in 24 studies (57%). The sensitivity and
specificity of NAM-PD were shown to be higher than
80% in 9 (38%) and 6 (25%) studies, respectively.
AUCs and predictive values/likelihood ratios were pro-
vided in 8 (19%) and 2 (5%) of the studies, respec-
tively. Agreement with a reference standard was
described in 6 (14%) of the articles, and 4 provided
evidence of an adequate agreement. Responsiveness
was investigated in 5 studies (12%; 3 studies used dis-
ease progression as the reference measure), and repeat-
ability in 4 studies (10%).
Technology Readiness. Of the studies, 26 (65%) used
NAM-PD evaluated as TRL 3. NAM-PD that were
proven in an operational environment (TRL9) were not
found.
Physical Activity
Number of Studies. A total of 18 (56%) studies
involved NAM-PD used by nondevelopers to charac-
terize physical activity, 5 (16%) reported on the vali-
dation of NAM-PD, 5 (16%) tested a mathematical
algorithm for NAM-PD, and 4 (12%) described an
NAM-PD or an idea.
Type of Technologies. The most frequently used sys-
tems were IMUs (22 studies, 69%).
Demographic Aspects. Of the studies, 19 (59%)
included 30 or fewer PwP. The most frequent mean/
median age group ranged from 61 to 70 years (15
studies, 71%), and in all studies, the mean/median age
of the participants was between 50 and 80 years.
Clinimetric Properties. Of the studies, 6 (21%) per-
formed data diagnostics prior to the statistical analy-
ses. The most frequently reported reference standard
was the UPDRS-III, which was used in 2 (7%) of the
studies.
Accuracy was reported in 13 studies (46%). Of
them, 4 (31%) reported sensitivity levels higher than
80%, and 2 (15%) identified specificity levels higher
than 80%. AUCs and predictive values/likelihood
ratios were provided in 3 (9%) and 1 (3%) of the
studies, respectively. Agreement with a reference stan-
dard was described in 4 (13%), with 2 of these studies
providing evidence of adequate agreement. Respon-
siveness was investigated in 5 (16%; 2 studies used
disease progression and 2 DBS treatment as the refer-
ence measure) and repeatability in 2 (6%) of the
studies.
Technology Readiness. Of the studies, 14 (50%)
included NAM-PD considered to be TRL 3, and 6
(21%) used NAM-PD that were TRL9.
Rigidity
Number of Studies. Of the studies, 6 (55%) reported
the validation of an NAM-PD that characterized rigid-
ity, 4 (36%) involved a NAM-PD used by nondevelop-
ers, and 1 (9%) tested a mathematical algorithm for
NAM-PD.
Type of Technologies. The most frequently used sys-
tems were IMUs (4 studies, 36%).
Demographic Aspects. Of the studies, 7 (64%)
included 30 or fewer PwP. The most frequently includ-
ed age group ranged from 61 to 70 years (4 studies,
50%), and the mean/median age of the participants in
all studies was between 50 and 80 years.
Clinimetric Properties. Of the studies, 3 (27%) per-
formed data diagnostics. The most frequently reported
reference standard was the UPDRS-III (3 studies, 27%).
Accuracy was reported in 2 (18%) of the studies,
and none showed a sensitivity or specificity higher
than 80%. AUCs and predictive values/likelihood
ratios were not provided in any of the studies.
Responsiveness and repeatability were investigated in
3 (27%; 2 used pharmacological interventions as the
reference measure) and 2 (18%) of the studies,
respectively.
Technology Readiness. Of the studies, 6 (55%) used
NAM-PD considered to be of a TRL 3, and none of
TRL9.
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NAM-PD for the Assessment of
Nonmotor Aspects
Number of Studies
Of the studies, 15 (63%) involved NAM-PD used
by nondevelopers, 7 (29%) reported the validation of
a NAM-PD, and 2 (8%) tested a mathematical algo-
rithm for NAM-PD.
Type of Technologies
The most frequently used systems were IMUs (7
studies, 29%), followed by virtual reality-based sys-
tems (6 studies, 25%) and software-based solutions (5
studies, 21%).
Demographic Aspects
Of the studies, 19 (79%) included 30 or fewer PwP.
The participants had a mean/median age ranging from
61 to 70 years in 17 (85%) of the studies that
reported this information.
Clinimetric Properties
Of the studies, 3 (13%) performed data diagnostics
prior to conducting any statistical analyses. The most
frequently reported reference standards were validated
tests/scales in 7 (29%) and expert diagnosis in 5
(21%) of the studies.
Accuracy was reported in 5 studies (21%). The sen-
sitivity and specificity were shown to be higher than
80% in 2 (40%) of them. AUCs were reported in 2
(8%), and predictive values/likelihood ratios in 1 (4%)
of the studies. Agreement with a reference standard
was described in 4 studies (17%). Two of them pro-
vided evidence of an adequate agreement. Responsive-
ness and repeatability were not investigated in any of
the studies.
Technology Readiness
A total of 11 (46%) studies assessed NAM-PD con-
sidered to be of a TRL3, and 3 (27%) NAM-PD of
TRL9.
NAM-PD for the Assessment of
Treatment Complications
Number of Studies
Ten studies (50%) tested a mathematical algorithm
for NAM-PD, 6 (30%) involved NAM-PD used by
non-developers, and 2 (10%) reported the validation
of an NAM-PD.
Type of Technologies
The most frequently used systems were IMUs (13
studies, 65%).
Demographic Aspects
Of the evaluated studies, 11 (55%) included 30 or
fewer PwP. The included participants had a mean/
median age ranging from 61 to 70 years in the 5
(63%) studies reporting this information.
Clinimetric Properties
Of the studies, 1 (5%) performed data diagnostics
prior to the statistical analyses. The most frequently
reported reference standards were expert diagnosis
and total score on the UPDRS (both with 3 studies,
16% each).
Accuracy was reported in 13 (68%) of the studies.
The sensitivity and specificity were higher than 80%
in 3 (23%) and 4 (31%) of the studies, respectively.
AUCs and predictive values/likelihood ratios were pro-
vided in 4 (20%) and 1 (5%) of the studies, respec-
tively. Agreement with a reference standard was
described in 1 study, which provided evidence of ade-
quate agreement. Responsiveness and repeatability
were investigated in 3 (15%) and 2 (10%) studies,
respectively. For the former, the methods used to
induce a change included DBS treatment (n5 1) and
pharmacological intervention (n5 1).
Technology Readiness
Of the studies, 7 (41%) assessed NAM-PD consid-
ered to be of a TRL3, and none included an NAM-
PD of TRL9.
NAM-PD That Completed the
Proof-of-Concept Stage (TRL 5)
A complete list of the systems that completed the
proof of concept stage and had some initial validation
in the laboratory can be found in the supplementary
material section.
Discussion
This work provides a panoramic overview of a decade
of innovation in the evaluation of Parkinsons disease
(2005-2015). The breadth of the study is reflected in the
substantial number of articles considered in this system-
atic approach (Supplementary Figure).
The evaluation of NAM-PD by disease domain, the
systematic approach, the inclusion of nonwearable
technologies, and the introduction of the TRL in this
field of scientific activity complement the existing ini-
tiatives on this topic.2,7-9 As previously mentioned,
this comprehensive initiative aims to provide the inter-
ested reader with the opportunity to extract relevant
data from the spreadsheet for personal purposes and
to set the stage for a common collection of qualitative
data in this highly dynamic research field. The analysis
provided in this manuscript presents only an example
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of how the data can be used and lays the groundwork
for some conclusions that can be considered in the fur-
ther development of the field.
Number and Type of Studies
Per Disease Domain
Within the different disease domains, studies that
primarily presented validation efforts were the most
frequent type. The exceptions were axial features,
physical activity, and nonmotor domains, for which
studies focusing on nondevelopers’ evaluations of
NAM-PD performance represented the largest portion.
For speech, several of the papers reported mathemati-
cal algorithms. All of these exceptions can be
explained by different reasons. For axial features, the
specific development of NAM-PD started early, which
enabled already relatively mature NAM-PD to be
available to nondevelopers. For physical activity, the
existence of wearable systems intended for other appli-
cations (eg, physical activity monitoring systems for
the general public) were available to nondevelopers
for use as NAM-PD. For nonmotor assessments, our
observations suggest that validation efforts have been
neglected, and a particular emphasis should be placed
on developing validated systems for the assessment of
nonmotor features of PD. Interestingly, for speech, the
existence of open databases may have favored the
development of new mathematical algorithms.
An interrelated fact pertains to the number of refer-
ences identified per domain. Axial features were the
most represented domain, with 213 articles included
in the detailed evaluation process. This highlights the
importance of this domain in the assessment of PD
from a clinical and PwP point of view; however, the
heterogeneity of this category (comprising different
aspects of the disease, eg, posture, gait, freezing of
gait, and balance) may also have contributed to this
result. The second most frequently studied domain
was bradykinesia (127 articles). This emphasis may be
related to the importance of bradykinesia in the assess-
ment of PD20 and its ability to be measured with
existing hardware (eg, IMUs)1. In contrast, NAM-PD
for rigidity and nonmotor features were rarely investi-
gated and thus represent a huge opportunity for tech-
nology developers given the relevance of these
domains in the management of PD and the quality of
life of PwP.21,22
Although not specifically presented in this systematic
review, the positive evaluations of individual NAM-
PD platforms that measure several aspects of the dis-
ease (see below) and the underinvestigation of certain
domains support the findings of previous literature
(eg, Ref. 23) in that such platforms seem more mean-
ingful. Of note, 110 (19%) of the 588 studies evaluat-
ed more than 1 disease domain.
Types of Technologies Used
The types of systems used to assess specific disease
domains were highly heterogeneous. However, IMUs
were the primary choice in most of the domains, and
publications using this type of NAM-PD are increasing
at a disproportional rate. The reason for this develop-
ment is obvious: The use of wearable technology in
the general population2 and the miniaturization of
sensors have created a new era in PD assessment.24 At
their current stage of development, IMUs are primarily
used to assess bradykinesia,25 tremors,26 and axial fea-
tures.27 Virtually all cardinal motor features (perhaps
with the exception of rigidity, for which only a small
number of studies are currently available) can be
quantified with these systems, at least in a research
setting. Nonetheless, their use in routine clinical care
needs to be defined (see also Ref. 28).
Clinimetric Testing and Lessons
Learned From the Field
A particularly important aspect for the successful
future development of the field toward clinical appli-
cability is to define useful standards and systems to
prevent the overinvestigation of specific aspects in
studies performing very similar experiments with
slightly different NAM-PD as well as to foster topics
that are currently underinvestigated. Based on the
results of this systematic evaluation of the recent
decade of NAM-PD research, consideration of the fol-
lowing points may contribute to this process.
First, many of the evaluated validation articles did
not report information on aspects that are essential to
understand the context in which the validation
occurred. Variables such as age, disease stage, and
validity parameters were inconsistently reported.
These parameters are crucial to ensure that the sys-
tems’ performances are replicable and can be ade-
quately interpreted when other PD populations are
investigated. The Standards for Reporting of Diagnos-
tic Accuracy guideline (STARD) could serve as an ade-
quate starting point to define the minimum set of
variables that should be included in future NAM-PD
validation studies.16
Second, the studies that are currently available in
the field do not sufficiently reflect the full PD spec-
trum. For example, most of the studies included a rel-
atively low number of participants. Moreover, most
studies focused on PwP aged in their 60s, with rela-
tively low Hoehn and Yahr stages. Larger studies that
are representative of the full spectrum of the disease
are needed to ensure that the performance of the
NAM-PD will be generalizable. This need could be
facilitated by collaborative initiatives. These initiatives
could also be essential in independently replicating
pilot results.29 In the studies evaluated in this review,
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only 8% confirmed their results in an independent
dataset.
Third, an inherent limitation of the NAM-PD field
is the absence of quantitative standards. Most of the
studied domains used the UPDRS-III as a reference.
Although acceptable, the limitations of this approach
have already been discussed.15,30-32 Our recommenda-
tion is for key players in the field to standardize the
validation of upcoming NAM-PD, ideally with quanti-
tative and objective parameters, and to foster open
datasets of already published studies.
Fourth, most of the studies used statistical correla-
tions instead of recommended methodologies to prove
diagnostic validity. Simple correlation approaches have
relevant drawbacks.17-19 From our perspective, diagnos-
tic validation requires the assessment of the perfor-
mance of a new system at the individual level. A
detailed description of the methods that can be used is
beyond the scope of this review; however, forming mul-
tidisciplinary teams exposed to this methodology is
highly recommended. This multidisciplinary approach
could also increase the applicability of NAM-PD in
realistic clinical scenarios (which is a key aspect for the
future translation of these technologies), and there is
clear evidence that this development process will benefit
from the participation of PwP.23,33
Fifth, 87% of the included studies were implemented
in clinical or laboratory settings and not in simulated
or real-life settings. As part of the validation process,
developers should be encouraged to test their systems
in the actual environment of their intended use.
Technology Readiness
A final exploratory aspect of our review was the
assessment of the TRL in evaluating the readiness of
an NAM-PD10 (Supplementary Table). Based on our
evaluation, a surprisingly low percentage of 6% of the
studies included NAM-PD that were TRL9. Only an
NAM-PD at this level justifies the hope of including
this system in clinical assessments in due course. Most
of these systems are commercialized for research and
not for clinical application. They include mainly accel-
erometers but also force plates and motion analysis
systems. Few software-based technologies and mathe-
matical algorithms reached a TRL 5. When we
examined the disease domains assessed by the most
mature systems, the most represented domains were
axial features, followed by bradykinesia, physical
activity, and tremors. A final aspect that needs to be
stressed is that no systems for home-based assessments
reached TRL9.
Study Limitations
Our evaluation has limitations. First, we tried to
cover all NAM-PD studies investigating the 12 PD
domains of interest that had been published in the
past 10 years, and we might have missed relevant
articles by using this approach. Specifically, the
defined period for which the search was conducted
may have led to the exclusion of relevant (earlier)
studies and (different) NAM-PD. Nonetheless, consid-
ering the short cycle of technological innovation34 and
the thorough selection process of the domains of inter-
est, it seems unlikely that this limitation had a relevant
impact on the general results and our conclusions. Sec-
ond, the inclusion of more than 1 rater may have
introduced inconsistencies into the data. However, 3
of the authors (A.S.F., M.E., and D.S.) counterchecked
for these inconsistencies and addressed them. Special
emphasis was placed on the TRL rating (all articles
were counterchecked by 1 author) and the implica-
tions of labeling a system as mature. Moreover, as the
database is shared publicly, any feedback on individu-
al studies/inconsistencies could be integrated in
updated versions.
Conclusion
This systematic review provides an overview of the
current options in the field of quantitative assessment
of the most important PD features and what these
technologies can provide in the near future. It may
serve as a foundation for the design and performance
of future studies in the field and may help increase
their quality and impact. In these studies, particular
emphasis should be placed on the combined efforts of
scientists to increase cohort sizes, provide measure-
ments in naturalistic environments, prevent the overin-
vestigation of singular topics, enhance the maturation
processes of assessment systems, and consider valida-
tion issues. Such efforts have the most probable poten-
tial of revolutionizing the diagnosis and treatment of
PD for both PwP and those who treat them.
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